SLC7A11在KRAS突变胰腺癌中的表达及临床意义  

The expression and clinical significance of SLC7A11 in KRAS mutant pancreatic cancer

作　　者：张萌[1] 刘旭明 麦皓尘 曾志芬[1] ZHANG Meng;LIU Xuming;MAI Haochen;ZENG Zhifen(General Medicine Department,Pathology Department,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510000,China;不详)

机构地区：[1]中山大学孙逸仙纪念医院全科医学科,广州510000 [2]中山大学孙逸仙纪念医院病理科,广州510000

出　　处：《实用医学杂志》2022年第24期3125-3128,3134,共5页The Journal of Practical Medicine

基　　金：广东省科技计划项目(编号:202201010856)。

摘　　要：目的了解SLC7A11在KRAS突变胰腺癌中的阳性表达率,并探讨其与胰腺癌分化、转移、分期及预后的关系。方法选取2019年1月1日至2021年12月31日入住中山大学孙逸仙纪念医院、手术病理确诊为胰腺癌、完成了KRAS基因检测且具备完整临床资料及后续随访条件的54例患者,其中KRAS突变27例,设为实验组;无KRAS突变27例,设为对照组。全部病例均检测手术病理组织的SLC7A11表达,并收集其一般情况、分化程度、淋巴结转移、肿瘤大小、疾病分期及生存期临床资料。比较两组胰腺癌SLC7A11表达的阳性率,并采用卡方检验分析SLC7A11的表达与上述研究因素的关系。结果KRAS突变胰腺癌肿瘤组织中的SLC7A11的阳性表达率显著高于对照组(P=0.002),且其与SLC7A11的阳性表达与更晚的疾病分期(P<0.001)、更差的组织学分级(P=0.003)、更多的淋巴结转移(P=0.038)、更短的生存期(P<0.001)相关,其差异具有统计学意义。结论KRAS突变的胰腺癌组织的SLC7A11阳性表达率高,对于基因检测提示KRAS突变的病例应进一步检测SLC7A11的表达;SLC7A11的阳性表达与更差的疾病预后相关,SLC7A11抑制剂极可能是胰腺癌的潜在靶向治疗药物。Objective To investigate the positive expression of SLC7A11 in KRAS mutant pancreas and the relationship with differentiation,metastasis,staging and prognosis of pancreatic cancer.Methods 54 patients admitted to Sun Yat-sen Memorial Hospital of Sun Yat-sen University,from January 1,2019 to December 31,2021,who were confirmed as pancreatic cancer by surgery and pathology,completed KRAS based detection,and had complete clinical data and follow-up conditions were selected.27 patients showed KRAS mutation in the base detection were set as the experimental group:27 patients without KRAS mutation were set as the control group.The expression of SLC7A11 in surgical and pathological tissues was detected in all cases,and clinical data such as general condition,differentiation degree,lymph node metastasis,tumor size,disease stage,survival period were collected.The positive expression of SLC7A11 was compared between the two groups,andChi square test was used to analyze the relationship between the expression of SLC7A11 and the above factors.Results The positive expression rate of SLC7A11 in KRAS mutant pancreatic cancer was significantly higher than that in the control group(P=0.002),and the positive expression of SLC7A11 was correlated with the later disease stage(P=0.000),the worse histological grade(P=0.003),the more lymph node metastasis(P=0.038)and the shorter survival period(P=0.000).The difference was statistically significant.Conclusions The positive expression rate of SLC7A11in pancreatic cancer tissues with KRAS mutation is high,and further detection of SLC7A11 expression should be carried out in cases with KRAS mutation.The positive expression of SLC7A11 is associated with worse disease prognosis.SLC7A11 inhibitors are likely to be potential targeted drugs for pancreatic cancer.

关 键 词：胰腺癌 SLC7A11 KRAS SLC7A11抑制剂 

分 类 号：R735.9[医药卫生—肿瘤]